Skip to NavigationSkip to content

Novartis’ Zykadia smashes Phase III target for lung cancer

Published on 23/09/16 at 09:12am

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating its efficacy in treating patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.

Zykadia, an orally-administered selective inhibitor of anaplastic lymphoma kinase, showed a significant improvement in progression-free survival in previously untreated patients compared to standard chemotherapy.

Alessandro Riva, global head of Oncology Development and Medical Affairs at Novartis Oncology, explained: "Zykadia has proven to be an important treatment option for ALK+ NSCLC patients who have progressed following treatment with crizotinib. We are pleased to see these topline results show promise in untreated patients with advanced disease, and look forward to sharing these data with regulatory authorities in the coming months."

Zykadia has been approved in 55 countries and generated $24 million in Q2 sales.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches